United Kingdom

People: Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

7:59pm BST
Change (% chg)

$-0.01 (-1.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Fenton, Dennis 

Dr. Dennis M. Fenton, Ph.D is board of directors since October 2016. From 1982 until his retirement in 2008, Dr. Fenton worked at Amgen, where he held positions of increasing responsibility, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President. Previously, Dr. Fenton worked as a researcher at Pfizer Central in New Product Development from 1977 to 1981. Dr. Fenton is currently an independent consultant and a member of the boards of directors of Portola Pharmaceuticals, a public pharmaceutical company, Pfenex Inc., a public clinicalstage biotechnology company, Omniox, Inc., a biotechnology company and Modern Meadow, Inc. a private company. Dr. Fenton previously served on the boards of directors of then-public life sciences companies Kythera (which was acquired by Allergan in 2015), Hospira (which was acquired by Pfizer in 2015), Dendreon Corp., Xenoport (which was acquired by Arbor Pharmaceuticals in 2016) and Genzyme Corporation (which was acquired by Sanofi Genzyme in 2011). He is also a member of the board of trustees of the Keck Graduate Institute. Dr. Fenton received a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --